Next generation proteomic cancer detection via liquid biopsy

Market potential

Market potential

Third party researches believe that the new liquid biopsy market could reach an addressable value size of $20-25bn by 2022 from circa $0.5bn today. We can distinguish 4 main categories (ranked by time to commercialization):
Third party researches believe that the new liquid biopsy market could reach an addressable value size of $20-25bn by 2022 from circa $0.5bn today. We can distinguish 4 main categories (ranked by time to commercialization):
  • Theragnostics ─ treatment strategy that combines therapeutics with diagnostics (companion diagnostics/cancer panels)
  • Monitoring therapy ─ tracking potential drug resistance and therapeutic response during therapy
  • Prognosis ─ predicting the likely course and outcome of disease (recurrence) during remission and eventually
  • Screening ─ testing the general population to detect cancer among asymptomatic patients
Stacks Image 34

Business model
(Short-to-middle term)

Business model
(Short-to-middle term)

In the near future, the first assessment of tumor will most likely remain via a tissue biopsy but “re-biopsies” will benefit from a liquid biopsy approach by avoiding risks associated with multiple invasive procedures and by reducing costs (>80% of patients undergo over 2 biopsies while >60% of patients over 3 biopsies). Additionally, patients whose tumors are located in hard-to-reach or high-risk areas will appreciate to resort to liquid biopsy alternatives.
Therefore, we will initially sell complementary multiplex cancer panel tests to hospitals/oncology centers for breast, prostate and lung cancer indications.
In the near future, the first assessment of tumor will most likely remain via a tissue biopsy but “re-biopsies” will benefit from a liquid biopsy approach by avoiding risks associated with multiple invasive procedures and by reducing costs (>80% of patients undergo over 2 biopsies while >60% of patients over 3 biopsies). Additionally, patients whose tumors are located in hard-to-reach or high-risk areas will appreciate to resort to liquid biopsy alternatives.
Therefore, we will initially sell complementary multiplex cancer panel tests to hospitals/oncology centers for breast, prostate and lung cancer indications.

Current stage

Current stage

We are currently collaborating with the University of Cambridge and the Tokyo Institute of Technology on the development of a prototype.
We are currently collaborating with the University of Cambridge and the Tokyo Institute of Technology on the development of a prototype.